BioStem Technologies (BSEM) CFO Brandon Poe reports option, RSU and stock holdings
Rhea-AI Filing Summary
BioStem Technologies, Inc. reported the initial equity holdings of its Chief Financial Officer, Brandon Poe. He holds stock options to acquire 38,814 shares of common stock at an exercise price of $6.48 expiring on August 19, 2035, and options over 117,401 shares at $5.50 expiring on February 11, 2036. These options vest 33% on the first anniversary of their respective grant dates, with the balance vesting in equal quarterly installments over the following two years. Poe also holds restricted stock units covering 8,469, 32,225, and 96,909 shares of common stock, each series vesting in equal quarterly installments over three years from its grant date or 33% after one year with the remainder vesting quarterly over the next two years, as applicable. Each restricted stock unit represents a contingent right to receive one share of common stock. In addition, he directly owns 45,734 shares of common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
POE BRANDON
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F2 | -- | -- | -- |
| holding | Restricted Stock Units F4, F3 | -- | -- | -- |
| holding | Restricted Stock Units F4, F5 | -- | -- | -- |
| holding | Restricted Stock Units F4, F6 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 156,215 shares (Direct);
Restricted Stock Units — 137,603 shares (Direct);
Common Stock — 45,734 shares (Direct)
Footnotes (6)
- F1. These options vest according to the following schedule: 33% will vest on August 19, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F2. These options vest according to the following schedule: 33% will vest on February 11, 2027, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F3. These restricted stock units vest in equal quarterly installments over three years from the grant date (September 15, 2024).
- F4. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F5. These restricted stock units vest according to the following schedule: 33% will vest on August 19, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
- F6. These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
Key Figures
Stock options at $6.48: 38,814 shares
Stock options at $5.50: 117,401 shares
RSU grant 1: 8,469 units
+5 more
8 metrics
Stock options at $6.48
38,814 shares
Options to buy common stock at $6.48 expiring August 19, 2035
Stock options at $5.50
117,401 shares
Options to buy common stock at $5.50 expiring February 11, 2036
RSU grant 1
8,469 units
Restricted stock units vesting quarterly over three years from September 15, 2024
RSU grant 2
32,225 units
Restricted stock units vesting 33% after one year, then quarterly over two years
RSU grant 3
96,909 units
Restricted stock units vesting 33% after one year, then quarterly over two years
Direct common shares
45,734 shares
Direct ownership of BioStem Technologies common stock
Option expiration 1
August 19, 2035
Expiration date for options over 38,814 shares at $6.48
Option expiration 2
February 11, 2036
Expiration date for options over 117,401 shares at $5.50
Key Terms
Stock Option (Right to Buy), Restricted Stock Units, exercise price, contingent right to receive one share, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy) with exercise prices and expirations"
Restricted Stock Units financial
"security_title: Restricted Stock Units tied to common stock vesting over time"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
exercise price financial
"conversion_or_exercise_price: 6.4800 and 5.5000 for stock option grants"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting in equal quarterly installments financial
"units vest in equal quarterly installments over the subsequent two year period"
FAQ
What does BioStem Technologies (BSEM) disclose about CFO Brandon Poe’s stock options?
BioStem Technologies discloses that CFO Brandon Poe holds stock options over 38,814 shares at $6.48 expiring August 19, 2035, and 117,401 shares at $5.50 expiring February 11, 2036. Both grants vest 33% after one year, then quarterly over two additional years.
How many restricted stock units does BSEM’s CFO Brandon Poe hold?
CFO Brandon Poe holds restricted stock units tied to 8,469, 32,225, and 96,909 shares of BioStem Technologies common stock. Each restricted stock unit represents a contingent right to receive one share and vests in scheduled installments over three years from the respective grant dates.
What are the vesting terms for Brandon Poe’s restricted stock units at BioStem Technologies (BSEM)?
Some restricted stock units vest in equal quarterly installments over three years from the September 15, 2024 grant date. Other RSU grants vest 33% on the one-year anniversary of their grant dates, with remaining units vesting in equal quarterly installments over the subsequent two years.
Does the Form 3 for BSEM show any recent insider buying or selling by the CFO?
The Form 3 for BioStem Technologies lists holdings only and shows no explicit buy or sell transactions for CFO Brandon Poe. It details his existing stock options, restricted stock units, and common stock position as of the reported date without recording market purchases or sales.
AI-generated analysis. How Rhea-AI works. Not financial advice.
